Shared on 07 Nov 25
Fair value Decreased 2.64%BONEX: Clinical Study Results Will Drive Long-Term Patient Outcome Improvements
Bonesupport Holding's analyst price target has been updated downward from SEK 401.80 to SEK 391.20, as analysts factor in slightly softer revenue growth forecasts and a higher discount rate. What's in the News Bonesupport announced positive results from a clinical study showing significantly improved patient-reported outcomes for CERAMENT G in single-stage revision surgery for periprosthetic joint infection of the hip (Key Developments).
Shared on 24 Oct 25
Fair value Decreased 4.28%Analysts have revised their price target for Bonesupport Holding from SEK 419.75 to SEK 401.80. This change reflects adjustments to growth and profitability assumptions.
Shared on 24 Apr 25
Fair value Decreased 1.50%FDA Submission And US Launch Will Drive Success
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
FDA Submission And US Launch Will Drive Success
AnalystConsensusTarget has decreased revenue growth from 44.3% to 38.4%, decreased profit margin from 35.1% to 31.5% and increased future PE multiple from 35.7x to 45.2x.
Shared on 09 Apr 25
FDA Submission And US Launch Will Drive Success
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 11%FDA Submission And US Launch Will Drive Success
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Increased 3.91%FDA Submission And US Launch Will Drive Success
AnalystConsensusTarget made no meaningful changes to valuation assumptions.